Transthyretin amyloidosis cardiomyopathy (attr-CM)

Clinical trials for Transthyretin amyloidosis cardiomyopathy (attr-CM) explained in plain language.

Never miss a new study

Get alerted when new Transthyretin amyloidosis cardiomyopathy (attr-CM) trials appear

Sign up with your email to follow new studies for Transthyretin amyloidosis cardiomyopathy (attr-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis

Disease control Recruiting now

This study tests the drug acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart, weakening it. Over 36 months, researchers measure whether acoramidis improves heart function and structure using cardiac …

Matched conditions: TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM)

Phase 4 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control

Last updated Jul 31, 2026 00:00 UTC

Transthyretin amyloidosis cardiomyopathy (attr-CM)

Get alerted when new Transthyretin amyloidosis cardiomyopathy (attr-CM) trials appear

Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis